Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02638493 · ClinicalTrials.gov registry record
The Compartmental Biology of HIV in the Male Genital Tract
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 26
- Enrollment target
NCT02638493: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT02638493 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02638493 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
Male participants taking tenofovir-emtricitabine (TDF/FTC) will provide semen and blood samples which will be analyzed to better understand the pharmacology of antiretroviral therapy in the male genital tract.
Primary Outcome
Samples will be analyzed for drug concentrations at the following time points post dose: 3, 6, 9, 12, 18 and 24 hours, and used to estimate clearance from semen from a 300mg dose of tenofovir.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-10 |
What the finished NCT02638493 record still lists
NCT02638493 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02638493 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02638493 about?
NCT02638493 is a clinical study titled "The Compartmental Biology of HIV in the Male Genital Tract". Male participants taking tenofovir-emtricitabine (TDF/FTC) will provide semen and blood samples which will be analyzed to better understand the pharmacology of antiretroviral therapy in the male genital tract.
What is the current status of trial NCT02638493?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2015-12. Estimated completion is 2016-10.
Who is sponsoring clinical trial NCT02638493?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia